Cancer as an Immune System Failure: Integrative Approaches

Abstract

Cancer is increasingly recognized as a disease of immune system failure, where chronic inflammation, driven by pathogens, environmental toxins, and potentially mRNA vaccine-related immune suppression, fosters tumor development. This article explores the intricate relationship between inflammation, cancer, and pathogens, emphasizing chronic inflammation’s role in creating a tumor- promoting microenvironment via cytokines (e.g., IL-6, TNF-α) and pathways (e.g., NF-κB, STAT3). Pathogens like Helicobacter pylori and Human Papillomavirus (HPV) trigger persistent inflammation, contributing to cancers such as gastric and cervical, while exploiting immunosuppressive tumor environments. Drawing on Dr. Patrick Soon-Shiong’s [30] thesis, we propose that cancer stems from an imbalance between immune effector and suppressor cells, potentially exacerbated by post-COVID-19 immune dysregulation. We evaluate two products—Electrocide™ and ANKTIVA®—for their ability to enhance T-cell activation and modulate local and systemic immune responses. Electrocide™ (oral) promotes gut mucosal immunity, while ANKTIVA® (injectable) excels in systemic immunity but offers limited mucosal protection. These products, alongside an anti-inflammatory diet, support detoxification, reduce inflammation, may enhance chemotherapy efficacy by improving tumor oxygenation and immune function. Integrative approaches combining immune-focused therapies, healthy habits and nutrition align offer promising strategies for cancer recovery and health optimization. Monitoring via blood markers, scans, and symptom tracking is recommended to assess efficacy.

Keywords:Cancer, Immune failure, Chronic inflammation, Pathogens, Nutraceuticals, T-Cell activation, Electrocide, Integrative therapy, Chemotherapy, Nutrition, Dr. Soon-Shiong

Abbreviations:CD4-Cluster of Differentiation 4; CD8-Cluster of Differentiation 8; DNA-Deoxyribonucleic Acid; GALT-Gut-Associated Lymphoid Tissue; HPV-Human Papillomavirus; ICD-International Classification of Diseases; IgG-Immunoglobulin G, IL-6-interleukin- 6; mRNA-Messenger Ribonucleic Acid; NF-κB-Nuclear Factor Kappa-light-chain-enhancer of activated B cells; NK -Natural Killer; NMIBC-Non-Muscle Invasive Bladder Cancer; SCFAs-Short-Chain Fatty Acids; SIgA-Secretory IgA; STAT3-Signal Transducer and Activator of Transcription 3; TME-Tumor Microenvironment; TNF-α-Tumor Necrosis Factor-Alpha; Tregs-Regulatory T Cells; WHO-World Health Organization

Introduction

Cancer as an immune system failure, according to Dr. Patrick Soon-Shiong’s thesis [30], posits that cancer results from the immune system’s failure to recognize and eliminate rogue cells, driven by an imbalance between immune “killer” cells (e.g., T-cells, natural killer cells) and suppressor cells. The maintenance of immune homeostasis is fundamental to human health, orchestrating defense against pathogens while preserving self-tolerance [17]. Dysregulation within this system can lead to increased susceptibility to infections or autoimmune pathologies [16,9]. Current therapeutic paradigms for infectious diseases, primarily vaccination and antiviral agents [32], and for autoimmune conditions, often involving immunosuppression or targeted biologics [19], face challenges including antimicrobial resistance and systemic side effects. Recent advancements in immunooncology underscore the critical role of immune evasion and chronic inflammation in tumorigenesis, shifting the understanding of cancer from solely a genetic disease to one profoundly influenced by immune dysfunction [5,11,13]. This paradigm offers novel therapeutic avenues focused on restoring effective anti-tumor immunity. Chronic inflammation—potentially worsened by toxins, poor diet, persistent viruses, and mRNA vaccine side effects—may foster conditions for cancer development and progression [22]. Rising rates of aggressive cancers in younger populations, potentially linked to immune suppression from COVID-19 or its vaccines, suggest lingering spike protein in tissues may cause long-term inflammation [23].

Overview - T-cell Activation Methods for Developing Immune Responsiveness Relative to Chronic Inflammation

Comparing a hypotonic oral antipathogen and an injectable Immunotherapy in terms of T-cell activation and systemic or local immune responses involves examining their administration routes, immune stimulation mechanisms, and outcomes based on available evidence. Below is a detailed comparison focusing on T-cell activation (particularly CD4+ and CD8+ T-cells) and the balance between local (mucosal) and systemic immune responses.

Hypotonic Oral Antipathogen: Electrocide™

Electrocide™ is an aqueous nutraceutical solution containing electrically active minerals that produce micro-electric currents, exhibiting broad-spectrum antipathogenic effects against bacteria, fungi, and viruses. It works by modulating bioelectric communication in mucosal epithelial cells and enhancing oxygen levels and nutrient absorption, promoting general wellness and accelerating symptom recovery, including from COVID-19 [24,26].

Mechanism and Delivery

Administered orally (with other potential routes), Electrocide™ targets Gut-Associated Lymphoid Tissue (GALT). Its hypotonic, mineral-based composition resists gut degradation, unlike protein- based immunogens, enhancing antigen uptake by intestinal cells [25,27].

Immune Response

a) Local: Induces robust mucosal immunity, particularly Secretory IgA (SIgA), critical for neutralizing gut pathogens. It promotes regulatory T cells (Tregs) to balance inflammation and support antigen-specific responses.
b) Systemic: Generates moderate systemic immunity (IgG, CD4+ Tregs), limited by gut tolerogenic responses. Gut microbiota- derived short-chain fatty acids (SCFAs) enhance Treg differentiation, reducing systemic inflammation.

Advantages: Non-invasive, easy to administer, and could be ideal for mass immunization. Strong gut mucosal immunity with potential systemic benefits.

Limitations: Weaker systemic T-cell activation compared to injectable routes.

Injectable Immunotherapy: ANKTIVA®

Mechanism and Delivery

Administered subcutaneously, intramuscularly, or intralymphatically, ANKTIVA® targets systemic lymphoid tissues (e.g., lymph nodes, spleen) [3,31]. “This platform, powered by ANKTIVA ®, is designed to activate and proliferate NK and T cells, restoring immune function”, [12,4].

Immune Response

a) Local: Minimal mucosal immunity unless paired with mucosal adjuvants. Subcutaneous hydrogels (e.g., hyaluronic acid) create antigen depots, sustaining release and reducing hypersensitivity.
b) Systemic: May induce high IgG levels and robust CD4+/CD8+ T-cell responses. Intralymphatic injections enhance T-cell activation with lower antigen doses.

Advantages: Potent systemic immunity, ideal for intracellular pathogens. Controlled antigen release reduces side effects.

Limitations: Invasive, requiring trained personnel. Minimal mucosal immunity, less effective for mucosal pathogens.

Delivery System Conclusions

a) Oral (Electrocide™): Best for gut mucosal immunity and immune regulation, with moderate CD4+ Treg activation, benefiting respiratory and other mucosal applications.
b) Injectable (ANKTIVA®): Superior for systemic CD4+/CD8+ T-cell activation but limited for mucosal pathogens. For gut pathogens, the oral route is preferred, while injectable delivery is optimal for systemic immunity.

Integrative Therapeutics to Aid Health and Cancer Recovery

Cancer is increasingly viewed as a disease of immune system failure, exacerbated by chronic inflammation, environmental toxins, and potentially oncogenic factors like the COVID-19 virus or its mRNA vaccines, as argued by Dr. Patrick Soon-Shiong [30]. Nutraceuticals like Electrocide™, Protein Enzyme Capsules, and Super Detox may support cancer recovery by reducing chronic inflammation, aiding detoxification, and indirectly enhancing immune function, particularly T-cell activation. These align with integrative approaches to cancer care and general health optimization through nutrition, which emphasizes supporting the body’s natural cleansing, protection, and repair mechanisms adjunctive to traditional cancer treatment.

Nutraceuticals in Cancer Support and Chemotherapy Efficacy

The nutraceuticals may enhance chemotherapy outcomes and support recovery by addressing inflammation, toxicity, and immune function:

Electrocide™

a) Mechanism: Disrupts negatively charged pathogens, improving oxygenation and reducing inflammation. This could enhance chemotherapy efficacy by making tumors less hypoxic, as hypoxia reduces treatment response in solid tumors like glioblastoma [21]. Improved oxygenation may also support T-cell infiltration, critical for ICD-induced immune responses [15].

By directly targeting and disrupting respiratory pathogens, ELECTROCIDE™ could help reduce viral or bacterial load in the respiratory tract, potentially shortening the duration or severity of infections. This could be particularly relevant for preventing pathogen replication at early stages of exposure.

Early studies, such as those related to post-COVID-19 wellness, indicate ELECTROCIDE™ contributes to symptom recovery, by supporting immune function and overall well-being during and after respiratory viral challenges [26].

ELECTROCIDE™ may finely tune T-cell activation and cytokine profiles, that might help redirect or dampen aberrant autoimmune responses without causing widespread immunosuppression [27].

While inflammation is a hallmark of immune activation, chronic, dysregulated inflammation drives autoimmune pathology [8,16]. ELECTROCIDE™’s immune modulation leads to a more controlled, effective resolution of inflammatory processes, that could mitigate tissue damage in autoimmune conditions [27].

b) Evidence: A study showed reduced anxiety, pain, and improved oxygen levels in 52 volunteers, suggesting general wellness benefits that could translate to better treatment tolerance [24].

Protein Enzyme Capsules

a) Mechanism: Proteolytic enzymes (e.g., serrapeptase, nattokinase) reduce inflammation and fibrin, potentially improving circulation and chemotherapy delivery. Herbal components like Milk Thistle support liver detoxification, crucial for metabolizing chemotherapeutic drugs.
b) Evidence: Studies suggest proteolytic enzymes reduce chemotherapy side effects like pain and inflammation, improving quality of life [26]. A study on pancreatic pro-enzymes showed anti-tumor efficacy in cancer models [13].

Super Detox (Activated Carbon)

a) Mechanism: Absorbs toxins, reducing chemotherapy-related side effects like diarrhoea and organ stress. This could improve treatment tolerance and preserve immune function, supporting T-cell and natural killer cell activity.
b) Evidence: Activated carbon has been studied as a drug delivery system, enhancing chemotherapy delivery to lymph nodes and reducing toxicity [10]. Its role in toxin adsorption may support organ function during treatment [28].

Synergy with Soon-Shiong’s Protocol

Soon-Shiong’s [30] outpatient protocol uses low-dose chemo/ radiation to expose cancer cells, stimulates T-cells and natural killer cells (e.g., via ANKTIVA®), and suppresses immune suppressor cells [5,6]. The nutraceuticals complement could include reducing inflammation (Electrocide™, Protein Enzyme Capsules), supporting detoxification (Protein Enzyme Capsules, Super Detox), and potentially enhancing T-cell function through a healthier tumor microenvironment (TME) [20,10,2,14]. For example, the oxygenation benefits of Electrocide™ could amplify the effects of low-dose chemo in exposing cancer cells, while Super Detox’s toxin adsorption could reduce side effects, allowing better adherence to immune-stimulating protocols [7,18,8].

Nutrition and Health Optimization

Nutrition supports immune health and cancer prevention by reducing inflammation and aiding detoxification. In addition, adequate sleep, water consumption and exercise are crucial [29]. Key connections include

i. Body Homeostasis: Nutraceuticals support systemic health— Electrocide™ improves oxygenation, Protein Enzyme Capsules aid organ function, and Super Detox reduces toxin burden, fostering immune activation.
ii. Detoxification: Protein Enzyme Capsules (Liver, Kidney, Gallbladder and Lymphatic Cleanses with proteolytic enzymes) and Super Detox support liver and kidney function, potentially mitigating chemotherapy toxicity.
iii. Immune Protection: By reducing inflammation and pathogen load, nutraceuticals enhance T-cell and natural killer cell activity, aligning with Soon-Shiong’s focus.

Systemic Support

i. Immunology: Nutraceuticals can reduce inflammation, supporting T-cell activation.
ii. Protein Synthesis: Enzymes aid tissue repair, improving immune cell access to tumours.
iii. Blood Flow: Enhanced oxygenation and circulation improve chemotherapy effectiveness and immune cell delivery.
iv. Gut-Brain Axis: Electrocide has been shown to support gut health by killing opportunistic pathogens locally, and reducing inflammation that impairs nutrient absorption. With the restored leaky gut, appropriate nutritional uptake can occur improving the absorption of nutrients by the brain and the rest of the body.
v. Monitoring Progress: Blood markers (e.g., C-reactive protein, T-cell counts) and symptom improvements (e.g., reduced fatigue, pain) track nutraceutical efficacy. Imaging and biomarkers monitor cancer progression.
vi. Dietary Connection: An anti-inflammatory diet (e.g., omega- 3s, antioxidants, fiber) complements nutraceuticals by reducing chronic inflammation and supporting gut health, aligning with Soon-Shiong’s view that poor diet contributes to immune suppression.

Discussion

Soon-Shiong’s [30] claim that COVID-19 and mRNA vaccines may promote cancer via immune suppression highlights the need for therapies restoring immune balance [16]. Nutraceuticals like Electrocide™ (in various delivery forms) and Super Detox may mitigate post-viral inflammation, supporting T-cell function and chemotherapy efficacy [1,15,21]. These are not replacements for conventional treatments but should be integrated under medical supervision, using blood analysis and symptom tracking to monitor progress adding scan technology.

Chronic Inflammation and Cancer

Chronic inflammation plays a pivotal role in cancer development and progression. Persistent inflammatory states promote DNA damage, inhibit apoptosis, and enhance tumor cell proliferation, angiogenesis, and immune evasion [18]. Key inflammatory mediators like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) activate oncogenic signaling pathways such as NF-κB and STAT3, creating a tumor-permissive microenvironment. Clinically, chronic inflammatory conditions like inflammatory bowel disease or hepatitis B infection significantly elevate the risk of colorectal and liver cancers, respectively. Moreover, infections by oncogenic pathogens (e.g., Helicobacter pylori, HPV) often drive sustained inflammation that accelerates tumorigenesis. Conversely, acute inflammation may aid in anti-tumor immunity by recruiting effector cells to eliminate transformed cells. Thus, inflammation functions as both a driver and potential regulator of tumor immunity, depending on context.

Conclusion

This article has critically reviewed the theoretical underpinnings and pre-clinical observations regarding ELECTROCIDE™, a novel aqueous nutritional supplement characterized by specific electrical properties. ELECTROCIDE™ may function as a multifaceted immunomodulator, potentially exerting both direct antipathogenic effects and indirect immune-enhancing properties. The hypothesis is that ELECTROCIDE™ may (1) augment host defenses against respiratory and mucosal pathogens by modulating innate and adaptive immune responses, and (2) offer a novel mechanism for immune rebalancing relevant to conditions of immune dysregulation, including certain autoimmune profiles. This exploration integrated existing in vitro and preliminary in vivo data with theoretical considerations to delineate the potential role of ELECTROCIDE™ within an integrative immunological framework.

The conceptualization of cancer as a failure of immune surveillance, often exacerbated by chronic inflammatory processes, provides a compelling framework for developing novel therapeutic strategies. The nutraceuticals Electrocide™, Protein Enzyme Capsules, and Super Detox are hypothesized to contribute to supportive cancer care by modulating inflammatory pathways, aiding detoxification, and enhancing T-cell activation, thereby aligning with principles of immune rebalancing in oncology. Nutrition amplifies these effects by supporting the body’s natural defenses. This integrative approach—combining nutraceuticals, immune-focused therapies, and optimal nutrition—offers a promising strategy for cancer treatment, recovery, and health optimization.

Acknowledgement

We acknowledge Mr. George Madiou for his invaluable assistance in preparation of this article.

Conflict of Interest

None.

References

1. Calder PC (2013) Feeding the immune system. Proc Nutr Soc 72(3): 299-309.
2. Chaitow, L, Wolever TMS, FitzGerald DJ (2021) Proteolytic enzymes in cancer treatment: A systematic review. Anticancer Research 41(7): 3213-3232.
3. Chamie K, Sam S Chang, Eugene Kramolowsky, Mark L Gonzalgo, Piyush Kumar Agarwal, et al. (2023) IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer. NEJM Evidence 2(1): EVIDoa2200167.
4. Chang S (2025) An Update on QUILT-3.032: Durable Complete Responses to NAI (ANKTIVA) Plus BCG Therapy in BCG-Unresponsive CIS With or Without Ta/T1 Papillary Disease and in Papillary Disease without CIS. [Conference Presentation]. AUA2025, Las Vegas, Nevada, United States.
5. Chen DS, Mellman I (2013) Oncology meets immunology: The cancer-immunity cycle. Immunity 39(1): 1-10.
6. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, et al. (2000) Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer 89(7): 1634-1646.
7. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917): 860-867.
8. Ferrucci L, Fabbri E (2018) Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nature Reviews Cardiology 15(9): 505-522.
9. Fragkou PC, Moschopoulos CD, Reiter R, Berger T, Skevaki C (2022) Host immune responses and possible therapeutic targets for viral respiratory tract infections in susceptible populations: a narrative review. Clin Microbiol Infect 28(10): 1328-1334.
10. Hagiwara A, Takahashi T, Ueda T, Iwamoto A, Torii T (1987) Activated carbon particles as anti-cancer drug carrier into regional lymph nodes. Anticancer Drug Des 1(4): 313-321.
11. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5): 646-674.
12. (2025), ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East. Nasdaq.
13. Isaacs LL (2022) Pancreatic proteolytic enzymes and cancer: New support for an old theory. Integr Cancer Ther 21:15347354221096077.
14. Kanazawa H, Terasawa T, Fukuyama Y (1985) Absorption of anticancer agents with activated carbon. Gan to Kagaku Ryoho. Cancer & Chemotherapy 12(7): 1319-1324.
15. Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31: 51-72.
16. Liu Y, Sawalha AH, Lu Q (2021) COVID-19 and autoimmune diseases. Curr Opin Rheumatol 33(2): 155-162.
17. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454(7203): 428-435.
18. Multhoff G, Molls M, Radons J (2012) Chronic inflammation in cancer development. Front Immunol 2: 98.
19. National Institute of Environmental Health Sciences. (n.d.). Autoimmune Diseases. Retrieved from https://www.niehs.nih.gov/health/topics/conditions/autoimmune.
20. Peran M, Lopez Ruiz E, Garcia MA, Nadaraia Hoke S, Brandt R, et al. (2017) A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: A pilot study focused on pancreatic and ovarian cancer. Sci Rep 7(1): 13998.
21. Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148(3): 399-408.
22. Seneff S, Nigh G (2021) Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. International Journal of Vaccine Theory, Practice, and Research 2(1): 38-79.
23. Soldati L, Guo Z, Godbole V, Saxena M, Soon Shiong P (2025) Characterization of lysate from NK-92 cells and its potential use as an immunotherapeutic modality. Cellular Immunology 413: 104951.
24. Sonnenschein L, Etyang T, Shah R, Frischer R, Rein G (2021) The effect of an aqueous electricidal solution on general well-being. Am J Biomed Sci & Res 13(4): 477-483.
25. Leonard Sonnenschein, Tiberious Etyang (2024) Eating Healthy (“The No White Diet”). Am J Biomed Sci & Res 24(4): 439-451.
26. Leonard Sonnenschein, Tiberious Etyang, Selene Manga, Erna Wong (2023) An Initial Evaluation of the Effectiveness of a Dietary Supplement Regimen on the Effects of Post-COVID Infection. Am J Biomed Sci & Res 18(6): 580-592.
27. Sonnenschein L, Etyang T (2025) Unlocking immunity: Electrocide™ – a novel approach. Am J Biomed Sci & Res 27(5): 786-790.
28. Sonnenschein L, Etyang T (2024) Connecting Microbiomes: From Soil to Human Health across Ecosystems. WSEAS Transactions on Environment and Development 20: 924-939.
29. Sonnenschein Leonard, Etyang Tiberious (2024) The Medical Importance of Activated Carbon for Detoxing. Am J Biomed Sci & Res 21(4): 397-401.
30. Soon Shiong P (2025) Dr. Patrick Soon-Shiong: You’re Being Lied to About Cancer, How It’s Caused, and How to Stop It [Video]. YouTube. https://www.youtube.com/watch?v=mgZaT-OriO8
31. (2024) U.S. Food and Drug Administration (FDA). FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive nonmuscle invasive bladder cancer. U.S. https://www.fda.gov/drugs/resources-information-approved-drugs/ fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer.
32. (n.d.). Vaccines and immunization. Retrieved from https://www.who.int/health-topics/vaccines-and-immunization.